Bridging studies at the very least - potentially any manufacturing change (eg replacing FBS or going to 3-D) could raise both safety and efficacy issues, so FDA may require larger scale trials.
This is particularly so in the absence of any definitive marker(s) for potency.
If it were me, I'd push ahead with the cells they've been using in the trials and start getting some revenues in before contemplating a potentially expensive change - remember (particularly for the MSB cells, maybe not so much for the Osiris cells) the manufacturing process is efficient and scalable as it is, and produces consistent, potent cells). Pricing will initially be high, so COGS not so important at first.
Get people used to cells as first line therapy, the bring in the Mark 2 new improved cells (might even command a price premium!).
- Forums
- ASX - By Stock
- Cell Therapy News/Articles
Bridging studies at the very least - potentially any...
-
-
- There are more pages in this discussion • 16,171 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
$1.10 |
Change
0.000(0.00%) |
Mkt cap ! $1.250B |
Open | High | Low | Value | Volume |
$1.09 | $1.13 | $1.08 | $5.380M | 4.893M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 69437 | $1.09 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.10 | 19999 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 69437 | 1.085 |
21 | 236832 | 1.080 |
7 | 104317 | 1.075 |
11 | 370859 | 1.070 |
2 | 53400 | 1.065 |
Price($) | Vol. | No. |
---|---|---|
1.095 | 19999 | 1 |
1.100 | 35400 | 3 |
1.105 | 32188 | 2 |
1.110 | 42480 | 5 |
1.120 | 97563 | 8 |
Last trade - 16.10pm 10/07/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO
Charles Armstrong
CEO
SPONSORED BY The Market Online